Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Gerald Hsu

Lymphoma · UCSF

View

Dr. Chadi Nabhan

Lymphoma · Ryght AI / USC

View

Dr. Mark Roschewski

Lymphoma · MSK

View

Dr. Jonathan Friedberg

Lymphoma · URMC

View

Dr. Matthew Matasar

Lymphoma · Rutgers Cancer Institute

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    DPDr. Daniel Persky

    Dr. Daniel Persky

    Hematology & Oncology · Lymphoma
    Banner - University Medical Center Tucson
    danielpersky

    Research

    A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma

    2024

    Via The Oncologist

    Research

    Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression

    2023

    Via Histology and Histopathology

    Research

    Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States

    2022

    Via Journal of Managed Care & Specialty Pharmacy

    Research

    Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia

    2022

    Via Value in Health

    Research

    Extranodal presentation in limited-stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001

    2022

    Via Haematologica

    Research

    Safety and Efficacy of Engineered Toxin Body MT-3724 in Relapsed or Refractory B-cell Non-Hodgkin's Lymphomas and Diffuse Large B-cell Lymphoma

    2022

    Via Cancer Research Communications

    Research

    Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

    2021

    Via Haematologica

    Research

    Outcomes of primary and secondary prophylaxis of chemotherapy-induced and febrile neutropenia in bendamustine plus rituximab regimens in patients with lymphoma and chronic lymphocytic leukemia: real-world, single-center experience

    2021

    Via Supportive Care in Cancer

    Research

    The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model

    2021

    Via Clinical Cancer Research

    Research

    Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy

    2021

    Via Future Oncology

    Research

    Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves

    2021

    Via Clinical Lymphoma, Myeloma & Leukemia

    Research

    Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017)

    2021

    Via Annals of Hematology

    Research

    Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma

    2021

    Via Viruses

    Research

    Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile

    2021

    Via Supportive Care in Cancer

    Research

    Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001

    2020

    Via Journal of Clinical Oncology